Aquatic Capital Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN

Aquatic Capital Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 73.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,831 shares of the biopharmaceutical company’s stock after selling 38,194 shares during the period. Aquatic Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $7,777,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Salomon & Ludwin LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Caitlin John LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $34,000. Traub Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Finally, E Fund Management Hong Kong Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $745.77 on Monday. The stock’s 50 day simple moving average is $769.73 and its 200 day simple moving average is $695.68. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The stock has a market capitalization of $78.84 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 2.00 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the company earned $12.07 EPS. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insiders Place Their Bets

In other news, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 over the last quarter. Corporate insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on REGN shares. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and boosted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $802.27.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.